Periostin as a blood biomarker of muscle cell fibrosis, cardiomyopathy and disease severity in myotonic dystrophy type 1

[1]  Chaofeng Sun,et al.  Periostin contributes to the adventitial remodeling of atherosclerosis by activating adventitial fibroblasts. , 2022, Atherosclerosis plus.

[2]  L. Sabourin,et al.  Periostin gene expression in neu-positive breast cancer cells is regulated by a FGFR signaling cross talk with TGFβ/PI3K/AKT pathways , 2021, Breast cancer research : BCR.

[3]  L. Sabourin,et al.  Periostin gene expression in neu-positive breast cancer cells is regulated by a FGFR signaling cross talk with TGFβ/PI3K/AKT pathways , 2021, Breast Cancer Research.

[4]  U. Demkow,et al.  The Usefulness of Urinary Periostin, Cytokeratin-18, and Endoglin for Diagnosing Renal Fibrosis in Children with Congenital Obstructive Nephropathy , 2021, Journal of clinical medicine.

[5]  D. Riethmacher,et al.  Periostin in Allergy and Inflammation , 2021, Frontiers in Immunology.

[6]  Meng Li,et al.  Inhibition of Postn Rescues Myogenesis Defects in Myotonic Dystrophy Type 1 Myoblast Model , 2021, Frontiers in Cell and Developmental Biology.

[7]  M. Estecio,et al.  Longitudinal increases in somatic mosaicism of the expanded CTG repeat in myotonic dystrophy type 1 are associated with variation in age-at-onset. , 2020, Human molecular genetics.

[8]  K. Harimaya,et al.  Periostin Promotes Fibroblast Migration and Inhibits Muscle Repair After Skeletal Muscle Injury , 2018, The Journal of bone and joint surgery. American volume.

[9]  J. Alonso,et al.  Periostin: A Matricellular Protein With Multiple Functions in Cancer Development and Progression , 2018, Front. Oncol..

[10]  B. Schoser,et al.  Core Clinical Phenotypes in Myotonic Dystrophies , 2018, Front. Neurol..

[11]  H. Lochmüller,et al.  Mass spectrometry‐based protein analysis to unravel the tissue pathophysiology in Duchenne muscular dystrophy , 2018, Proteomics. Clinical applications.

[12]  F. Muntoni,et al.  MRC Centre Neuromuscular Biobank (Newcastle and London): Supporting and facilitating rare and neuromuscular disease research worldwide , 2017, Neuromuscular Disorders.

[13]  L. Mestroni,et al.  Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathy , 2017, Open Heart.

[14]  M. Farrugia,et al.  Elevated plasma levels of cardiac troponin-I predict left ventricular systolic dysfunction in patients with myotonic dystrophy type 1: A multicentre cohort follow-up study , 2017, PloS one.

[15]  Jin-Sung Park,et al.  Quantitative Assessment of Trunk Muscles Involvement in Patients with Myotonic Dystrophy Type 1 Using a Whole Body Muscle Magnetic Resonance Imaging , 2017, European Neurology.

[16]  G. Meola,et al.  High-sensitive cardiac troponin T (hs-cTnT) assay as serum biomarker to predict cardiac risk in myotonic dystrophy: A case-control study. , 2016, Clinica chimica acta; international journal of clinical chemistry.

[17]  G. Bassez,et al.  Unravelling the myotonic dystrophy type 1 clinical spectrum: A systematic registry-based study with implications for disease classification. , 2016, Revue neurologique.

[18]  D. Swandulla,et al.  Proteomic analysis of dystrophin deficiency and associated changes in the aged mdx-4cv heart model of dystrophinopathy-related cardiomyopathy. , 2016, Journal of proteomics.

[19]  L. Maves,et al.  Skeletal muscle fiber type: using insights from muscle developmental biology to dissect targets for susceptibility and resistance to muscle disease , 2016, Wiley interdisciplinary reviews. Developmental biology.

[20]  G. Hillis,et al.  Structural and electrical cardiac abnormalities are prevalent in asymptomatic adults with myotonic dystrophy , 2016, Heart.

[21]  B. Engelen,et al.  Cognitive behaviour therapy plus aerobic exercise training to increase activity in patients with myotonic dystrophy type 1 (DM1) compared to usual care (OPTIMISTIC): study protocol for randomised controlled trial , 2015 .

[22]  L. Kritharides,et al.  Myotonic dystrophy and the heart: A systematic review of evaluation and management. , 2015, International journal of cardiology.

[23]  G. Meola,et al.  Myotonic dystrophies: An update on clinical aspects, genetic, pathology, and molecular pathomechanisms. , 2015, Biochimica et biophysica acta.

[24]  L. Køber,et al.  Myocardial fibrosis in patients with myotonic dystrophy type 1: a cardiovascular magnetic resonance study , 2014, Journal of Cardiovascular Magnetic Resonance.

[25]  Paola Gaia,et al.  Plasma microRNAs as biomarkers for myotonic dystrophy type 1 , 2014, Neuromuscular Disorders.

[26]  G. Meola,et al.  Report of the first Outcome Measures in Myotonic Dystrophy type 1 (OMMYD-1) international workshop Clearwater, Florida, November 30, 2011 , 2013, Neuromuscular Disorders.

[27]  J. Bourke,et al.  Subepicardial dysfunction leads to global left ventricular systolic impairment in patients with limb girdle muscular dystrophy 2I , 2013, European journal of heart failure.

[28]  L. Køber,et al.  Cardiac manifestations of myotonic dystrophy type 1. , 2012, International journal of cardiology.

[29]  Xiaolun Sun,et al.  A brief review of biomarkers for preventing and treating cardiovascular diseases , 2012, Journal of cardiovascular disease research.

[30]  D. Bluemke,et al.  Assessment of cardiac involvement in myotonic muscular dystrophy by T1 mapping on magnetic resonance imaging. , 2012, Heart rhythm.

[31]  R. Krahe,et al.  The myotonic dystrophies: molecular, clinical, and therapeutic challenges , 2012, The Lancet Neurology.

[32]  B. Cowan,et al.  Evaluation of left ventricular torsion by cardiovascular magnetic resonance , 2012, Journal of Cardiovascular Magnetic Resonance.

[33]  Y. Pinto,et al.  Structural and functional cardiac changes in myotonic dystrophy type 1: a cardiovascular magnetic resonance study , 2012, Journal of Cardiovascular Magnetic Resonance.

[34]  T. Baudino,et al.  Deletion of periostin reduces muscular dystrophy and fibrosis in mice by modulating the transforming growth factor-β pathway , 2012, Proceedings of the National Academy of Sciences.

[35]  A. Blamire,et al.  Left ventricular torsion, energetics, and diastolic function in normal human aging. , 2012, American journal of physiology. Heart and circulatory physiology.

[36]  A. Blamire,et al.  Impaired cardiac function in chronic fatigue syndrome measured using magnetic resonance cardiac tagging , 2011, Journal of internal medicine.

[37]  S. Olesen,et al.  Na+ channel distribution and electrophysiological heterogeneities in guinea pig ventricular wall. , 2011, American journal of physiology. Heart and circulatory physiology.

[38]  K. Strimbu,et al.  What are biomarkers? , 2010, Current opinion in HIV and AIDS.

[39]  Ruhang Tang,et al.  Periostin is a novel factor in cardiac remodeling after experimental and clinical unloading of the failing heart. , 2009, The Annals of thoracic surgery.

[40]  C. Angelini,et al.  Risk of arrhythmia in type I myotonic dystrophy: the role of clinical and genetic variables , 2009, Journal of Neurology, Neurosurgery, and Psychiatry.

[41]  D. Zipes,et al.  Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. , 2008, The New England journal of medicine.

[42]  Krishnaswamy Chandrasekaran,et al.  Twist mechanics of the left ventricle: principles and application. , 2008, JACC. Cardiovascular imaging.

[43]  R. Markwald,et al.  Periostin Is Required for Maturation and Extracellular Matrix Stabilization of Noncardiomyocyte Lineages of the Heart , 2008, Circulation research.

[44]  B. Cowan,et al.  Impaired subendocardial contractile myofiber function in asymptomatic aged humans, as detected using MRI. , 2006, American journal of physiology. Heart and circulatory physiology.

[45]  W. Groh,et al.  Prevalence of structural cardiac abnormalities in patients with myotonic dystrophy type I. , 2004, American heart journal.

[46]  C. Lau,et al.  Heterogeneity of sodium current in atrial vs epicardial ventricular myocytes of adult guinea pig hearts. , 2002, Journal of molecular and cellular cardiology.

[47]  L. Potvin,et al.  A 10-year study of mortality in a cohort of patients with myotonic dystrophy , 1999, Neurology.